Ranitidine Tablet
Product Images NDC 64980-637

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Ranitidine (NDC 64980-637). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ranitidine-150mg-30ct (Ranitidine 150mg 30ct)

Ranitidine Tablets, USP 150 mg oral tablets label by Rising Pharma Holdings, Inc. The label states to dispense in original container with 30 tablets. It includes usage instructions such as using within 3 months (90 days) after first opening and discarding after a specified date. Manufactured by VKT Pharma in India. Storage instructions and a barcode are also present.*

FDA Label Image

Ranitidine-300mg-30ct (Ranitidine 300mg 30ct)

Ranitidine Tablets, USP 300 mg oral tablets by Rising Pharma Holdings, Inc. The label indicates a quantity of 30 tablets in the original container. It includes warnings about usage within 3 months after bottle opening and storage instructions at controlled room temperature. Manufactured by VKT Pharma in India.*

FDA Label Image

Ranitidine-companylogo (Ranitidine Companylogo)

FDA Label Image

Ranitidine-hcl-struc (Ranitidine HCl Struc)

Chemical structure of ranitidine hydrochloride, showing its molecular arrangement including a furan ring, nitro group, and various functional groups consistent with its identity as the active ingredient in ranitidine tablets.*

FDA Label Image

Ranitidine-table1 (Ranitidine Table1)

A data table titled 'Ranitidine Pharmacokinetics in Pediatric Patients Following Oral Dosing' showing population age, sample size (n), dosage form and dose, and pharmacokinetic parameters Cmax and Tmax for gastric or duodenal ulcer patients aged 3.5 to 16 years, with 12 patients receiving tablets dosed at 1 to 2 mg/kg, displaying a Cmax range of 54 to 492 ng/mL and a Tmax of 2.0 hours.*

FDA Label Image

Ranitidine-table2 (Ranitidine Table2)

A data table titled 'Effect of Oral Ranitidine Tablets on Gastric Acid Secretion' showing percentage inhibition of gastric acid output at different doses (75-80 mg, 100 mg, 150 mg, 200 mg) over various time intervals after dosing, including basal, nocturnal, betazole, pentagastrin, and meal conditions.*

FDA Label Image

Ranitidine-table3 (Ranitidine Table3)

A data table titled 'Duodenal Ulcer Patient Healing Rates' comparing healing outcomes for Ranitidine Tablets versus Placebo at Weeks 2 and 4. It lists the number of patients entered and healed/evaluable counts with percentages for outpatient groups, showing higher healing rates for ranitidine at both time points.*

FDA Label Image

Ranitidine-table4 (Ranitidine Table4)

A data table titled 'Mean Daily Doses of Antacid' comparing ranitidine tablets and placebo in two groups: 'Ulcer Healed' and 'Ulcer Not Healed.' The table shows lower mean daily doses for ranitidine tablets compared to placebo in both groups.*

FDA Label Image

Ranitidine-table5 (Ranitidine Table5)

A data table titled "Duodenal Ulcer Prevalence" summarizing results from double-blind, multicenter, placebo-controlled trials. It compares the prevalence of duodenal ulcers over 0-4, 0-8, and 0-12 months between Ranitidine tablets (RAN) and placebo (PLC) in USA and foreign patient groups, including the number of patients per group. Statistical notes define RAN as ranitidine tablets, PLC as placebo, and indicate significant differences.*

FDA Label Image

Ranitidine-table6 (Ranitidine Table6)

A data table titled 'Gastric Ulcer Patient Healing Rates' comparing healing rates of patients treated with Ranitidine tablets versus placebo. It shows patient numbers entered and healed/evaluable counts with percentages at Weeks 2 and 6 for outpatient groups, noting permitted use of antacids and a statistical significance marker.*

FDA Label Image

Ranitidine-table7 (Ranitidine Table7)

A data table titled 'Erosive Esophagitis Patient Healing Rates' comparing healing rates in patients treated with a placebo versus ranitidine tablets USP 150 mg taken four times daily, across weeks 4, 8, and 12. The table shows the number and percentage of healed patients over evaluable patients for each group and time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.